Literature DB >> 2952641

Organization of the gene encoding the human beta-hexosaminidase alpha-chain.

R L Proia, E Soravia.   

Abstract

The lysosomal enzyme, beta-hexosaminidase, is composed of two chains, alpha and beta. In Tay-Sachs disease, mutations in the gene encoding the alpha-chain produce a beta-hexosaminidase deficiency that results in the storage of its natural substrate, GM2 ganglioside. To obtain the background information for the eventual identification of the mutational errors in Tay-Sachs disease and to determine possible relationships between protein and gene structure, we have characterized the intron-exon organization of the human beta-hexosaminidase alpha-chain gene. Several overlapping clones were isolated from human genomic libraries constructed in cosmid and bacteriophage vectors. The cloned genomic DNA was analyzed by restriction endonuclease mapping, Southern blotting, and DNA sequencing. It was determined that the alpha-chain gene is approximately 35 kilobases long and is split into 14 exons. Sequences which resemble the "TATA" and "CAAT" transcriptional regulatory motifs are present at the 5' end of the gene. Differential transcription or processing of the most 3' exon of the gene results in two alpha-chain mRNAs with different 3'-untranslated regions. The first exon of the gene encodes the amino-terminal portion of the alpha-chain which is removed during the proteolytic maturation of the enzyme, raising the possibility that this segment may exist as a functional domain.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2952641

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Cloning and sequence analysis of a cDNA encoding the alpha-subunit of mouse beta-N-acetylhexosaminidase and comparison with the human enzyme.

Authors:  T Beccari; J Hoade; A Orlacchio; J L Stirling
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

2.  A double mutation in exon 6 of the beta-hexosaminidase alpha subunit in a patient with the B1 variant of Tay-Sachs disease.

Authors:  P J Ainsworth; M B Coulter-Mackie
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

3.  Characterization of the human lysosomal alpha-glucosidase gene.

Authors:  L H Hoefsloot; M Hoogeveen-Westerveld; A J Reuser; B A Oostra
Journal:  Biochem J       Date:  1990-12-01       Impact factor: 3.857

4.  Frequency of the Tay-Sachs disease splice and insertion mutations in the UK Ashkenazi Jewish population.

Authors:  E C Landels; I H Ellis; A H Fensom; P M Green; M Bobrow
Journal:  J Med Genet       Date:  1991-03       Impact factor: 6.318

Review 5.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

6.  Do exons code for structural or functional units in proteins?

Authors:  T W Traut
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

7.  The 5' splice site: phylogenetic evolution and variable geometry of association with U1RNA.

Authors:  M Jacob; H Gallinaro
Journal:  Nucleic Acids Res       Date:  1989-03-25       Impact factor: 16.971

8.  Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group.

Authors:  R Myerowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Beta-hexosaminidase splice site mutation has a high frequency among non-Jewish Tay-Sachs disease carriers from the British Isles.

Authors:  E C Landels; P M Green; I H Ellis; A H Fensom; M Bobrow
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

10.  A pseudodeficiency allele common in non-Jewish Tay-Sachs carriers: implications for carrier screening.

Authors:  B L Triggs-Raine; E H Mules; M M Kaback; J S Lim-Steele; C E Dowling; B R Akerman; M R Natowicz; E E Grebner; R Navon; J P Welch
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.